Literature DB >> 25666432

A novel class of ruthenium-based photosensitizers effectively kills in vitro cancer cells and in vivo tumors.

Jamie Fong1, Kamola Kasimova2, Yaxal Arenas1, Pavel Kaspler1, Savo Lazic1, Arkady Mandel1, Lothar Lilge3.   

Abstract

The photo-physical and photo-biological properties of two small (<2 kDa), novel Ru(ii) photosensitizers (PSs) referred to as TLD1411 and TLD1433 are presented. Both PSs are highly water-soluble, provide only very limited luminescence emission at 580-680 nm following excitation at 530 nm, and demonstrate high photostability with less than 50% photobleaching at radiant exposures H = 275 J cm(-2) (530 nm irradiation). It was previously shown that these two photosensitizers exhibit a large singlet oxygen ((1)O2) quantum yield (Φ (Δ) ∼0.99 in acetonitrile). Their photon-mediated efficacy to cause cell death (λ = 530 nm, H = 45 J cm(-2)) was tested in vitro in colon and glioma cancer cell lines (CT26.WT, CT26.CL25, F98, and U87) and demonstrated a strong photodynamic effect with complete cell death at concentrations as low as 4 and 1 μM for TLD1411 and TLD1433, respectively. Notably, dark toxicity was negligible at concentrations less than 25 and 10 μM for TLD1411 and TLD1433, respectively. The ability of the PSs to initiate Type I photoreactions was tested by exposing PS-treated U87 cells to light under hypoxic conditions (pO2 < 0.5%), which resulted in a complete loss of the PDT effect. In vivo, the maximum tolerated doses 50 (MTD50) were determined to be 36 mg kg(-1) (TLD1411) and 103 mg kg(-1) (TLD1433) using the BALB/c murine model. In vivo growth delay studies in the subcutaneous colon adenocarcinoma CT26.WT murine model were conducted at a photosensitizer dose equal to 0.5 and 0.2 MTD50 for TLD1411 and TLD1433, respectively. 4 hours post PS injection, tumours were irradiated with continuous wave or pulsed light sources (λ = 525-530 nm, H = 192 J cm(-2)). Overall, treatment with continuous wave light demonstrated a higher tumour destruction efficacy when compared to pulsed light. TLD1433 mediated PDT resulted in statistically significant longer animal survival compared to TLD1411. Two-thirds of TLD1433-treated mice survived more than 100 days (p < 0.01) whereas TLD1411-treated mice did not survive longer than 20 days. Here we present evidence that two novel PSs have very potent photo-biological properties and are able to cause PDT-mediated cell death in both in vitro cell culture models and in vivo tumour regression.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25666432     DOI: 10.1039/c4pp00438h

Source DB:  PubMed          Journal:  Photochem Photobiol Sci        ISSN: 1474-905X            Impact factor:   3.982


  32 in total

1.  Predictive Strength of Photophysical Measurements for in Vitro Photobiological Activity in a Series of Ru(II) Polypyridyl Complexes Derived from π-Extended Ligands.

Authors:  Christian Reichardt; Susan Monro; Fabian H Sobotta; Katsuya L Colón; Tariq Sainuddin; Mat Stephenson; Eric Sampson; John Roque; Huimin Yin; Johannes C Brendel; Colin G Cameron; Sherri McFarland; Benjamin Dietzek
Journal:  Inorg Chem       Date:  2019-02-14       Impact factor: 5.165

Review 2.  Critical discussion of the applications of metal complexes for 2-photon photodynamic therapy.

Authors:  Johannes Karges; Hui Chao; Gilles Gasser
Journal:  J Biol Inorg Chem       Date:  2020-11-04       Impact factor: 3.358

3.  Photoactivated in Vitro Anticancer Activity of Rhenium(I) Tricarbonyl Complexes Bearing Water-Soluble Phosphines.

Authors:  Sierra C Marker; Samantha N MacMillan; Warren R Zipfel; Zhi Li; Peter C Ford; Justin J Wilson
Journal:  Inorg Chem       Date:  2018-01-11       Impact factor: 5.165

Review 4.  New photosensitizers for photodynamic therapy.

Authors:  Heidi Abrahamse; Michael R Hamblin
Journal:  Biochem J       Date:  2016-02-15       Impact factor: 3.857

5.  Ruthenium Photosensitizers for NIR PDT Require Lowest-Lying Triplet Intraligand (3IL) Excited States.

Authors:  Liubov M Lifshits; John A Roque; Elamparuthi Ramasamy; Randolph P Thummel; Colin G Cameron; Sherri A McFarland
Journal:  J Photochem Photobiol       Date:  2021-09-15

6.  Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers.

Authors:  Karan Arora; Mackenzie Herroon; Malik H Al-Afyouni; Nicholas P Toupin; Thomas N Rohrabaugh; Lauren M Loftus; Izabela Podgorski; Claudia Turro; Jeremy J Kodanko
Journal:  J Am Chem Soc       Date:  2018-10-22       Impact factor: 15.419

7.  Os(II) Oligothienyl Complexes as a Hypoxia-Active Photosensitizer Class for Photodynamic Therapy.

Authors:  John A Roque; Patrick C Barrett; Houston D Cole; Liubov M Lifshits; Evan Bradner; Ge Shi; David von Dohlen; Susy Kim; Nino Russo; Gagan Deep; Colin G Cameron; Marta E Alberto; Sherri A McFarland
Journal:  Inorg Chem       Date:  2020-10-30       Impact factor: 5.165

8.  Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433.

Authors:  Susan Monro; Katsuya L Colón; Huimin Yin; John Roque; Prathyusha Konda; Shashi Gujar; Randolph P Thummel; Lothar Lilge; Colin G Cameron; Sherri A McFarland
Journal:  Chem Rev       Date:  2018-10-08       Impact factor: 60.622

9.  Bis[pyrrolyl Ru(ii)] triads: a new class of photosensitizers for metal-organic photodynamic therapy.

Authors:  Deborah A Smithen; Susan Monro; Mitch Pinto; John Roque; Roberto M Diaz-Rodriguez; Huimin Yin; Colin G Cameron; Alison Thompson; Sherri A McFarland
Journal:  Chem Sci       Date:  2020-10-06       Impact factor: 9.825

10.  NIR-Absorbing RuII Complexes Containing α-Oligothiophenes for Applications in Photodynamic Therapy.

Authors:  Liubov M Lifshits; John A Roque; Houston D Cole; Randolph P Thummel; Colin G Cameron; Sherri A McFarland
Journal:  Chembiochem       Date:  2020-09-25       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.